RO   EN PROJECT LEADER UNIVERSITY OF MEDICINE AND PHARMACY CLUJ-NAPOCA
AMPEROMETRIC IMMUNOSENSOR FOR OVARIAN AND UTERINE CANCER BIOMARKERS


Home
Team Members
Objectives
Stages
Results
Other Information
Contact


General Information


AMPEROMETRIC IMMUNOSENSOR FOR OVARIAN AND UTERINE CANCER BIOMARKERS

Project number PN-II-ID-PCE-2011-3-0355

Project director: Prof. dr. Robert Sandulescu
Host Institution: ''Iuliu Hatieganu'' University of Medicine and Pharmacy Cluj-Napoca
Time schedule: october 2009 - october 2016
Contract value: 1500000 RON
Financed by: UEFISCDI
Contract no: 338/2011

Keywords

cancer biomarkers, nanostructures, immunosensors, nanobiolabels, screen-printed electrodes

Abstract

Increased levels of tumor markers in human serum are associated with patients with cancer, one of the leading causes of mortality. The determination of serum tumor markers plays an important role in screening for a disease, in diagnosing a disease, in determining the prognosis of a disease and in assessing the activity and complications of the disease, in monitoring the therapy in the tumor prevention stage, as well as for the follow-up examination during therapy, in the management of the illness for relapse detection for the patients with certain tumor-associated disease. Thus, the detection of tumor marker levels in human serum is absolutely necessary in clinical assay.

The first amperometric immunosensor for tumor markers was reported in 1979 (Aizawa et al., 1979), which was used for the determination of human chorionic gonadotropin (hCG) based on a competitive immunoassay. Monoclonal anti-hCG was immobilized on an amperometric oxygen electrode. Catalase-labeled-hCG and hCG in the sample competed for binding sites of immobilized anti-hCG on the electrode surface. After a washing step to remove nonspecifically bound hCG, the sensor was then reacted with the substrates. Membrane-bound catalase generated oxygen that was sensed by the oxygen electrode.

Since then different other electrochemical immunosensors for the quantification of tumors markers have been developed, as for example: immunosensor for cancer biomarker prostate specific antigen (PSA) with a detection limit of 0.5 pg/mL, immunosensors for carbohydrate antigen 19-9 (CA 19-9) for gastric carcinoma and for ovarian carcinoma antigen 125 (CA 125) with the limits of detection of 0.2 and 0.4 U/mL, respectively, immunosensors for carcinoembryonic antigen and for ?-fetoprotein for testicular cancer with the detection limits down to 3.2 and 4.0 pg/mL, immunosensor for carcinoembryonic antigen with detection limit down to 6.7 pg/mL.

The MUC1 gene encodes a type-I transmembrane glycoprotein that is expressed on the apical surface of most simple epithelia, including mammary gland, female reproductive tract, lung, kidney, stomach, gall bladder, and pancreas as well as some non-epithelial cell types.

Recent immunological studies suggest that MUC1 is a potential marker and a prognosis factor in diagnosis of ovarian cancer and endometriosis.

The research project proposed the elaboration of a novel series of immunosensors based on MUC1 and tumor MUC1 proteins, which can be a specific and sensitive alternative to currently more or less invasive, immunohistochemical methods actually used. Once the tumor proteins in blood successfully detected, will be followed by the design and construction of a noninvasive, specific and sensitive diagnostic device for biological fluids.

Reg. potentialilor contractori : 418

CUI 4288047